Bobak R. Azamian Sells 8,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 8,000 shares of the business’s stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $14.56, for a total transaction of $116,480.00. Following the transaction, the chief executive officer now owns 1,116,613 shares in the company, valued at $16,257,885.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock opened at $14.93 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.40 and a quick ratio of 16.40. The firm’s 50-day moving average is $15.51 and its two-hundred day moving average is $16.05. Tarsus Pharmaceuticals, Inc. has a 12 month low of $10.80 and a 12 month high of $21.47. The company has a market capitalization of $398.21 million, a PE ratio of -5.37 and a beta of 0.67.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last issued its earnings results on Wednesday, November 9th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.14. Tarsus Pharmaceuticals had a negative net margin of 324.99% and a negative return on equity of 34.24%. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Oppenheimer reduced their target price on shares of Tarsus Pharmaceuticals from $66.00 to $43.00 in a research note on Thursday, November 10th.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in TARS. Dimensional Fund Advisors LP raised its stake in shares of Tarsus Pharmaceuticals by 221.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock valued at $485,000 after acquiring an additional 19,865 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Tarsus Pharmaceuticals by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after acquiring an additional 1,402 shares during the period. UBS Group AG raised its stake in shares of Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after acquiring an additional 1,142 shares during the period. Invesco Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 17.1% in the 1st quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock valued at $471,000 after acquiring an additional 4,078 shares during the period. Finally, State Street Corp raised its stake in shares of Tarsus Pharmaceuticals by 2.4% in the 1st quarter. State Street Corp now owns 132,883 shares of the company’s stock valued at $2,235,000 after acquiring an additional 3,141 shares during the period. 76.82% of the stock is owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.